NEW YORK – In spite of having the world's highest number of life science patents per capita, a highly developed academic research infrastructure, and entrepreneurial know-how, Israel still has trouble commercializing its discoveries due to a number of factors, mostly financing. But the Israeli biotech industry is finally coming of age, according to 14 company presentations at this week's Tel Aviv Stock Exchange (TASE)-NASDAQ Biomed Conference held at NASDAQ's New York headquarters.